Skip to main content
. 2021 Mar 31;2021:8866446. doi: 10.1155/2021/8866446

Table 1.

Baseline characteristics of the study population.

Baseline characteristics N = 2752
Female sex, n (%) 1429 51.9
Age, mean (SD) 70.4 11.3

Ethnicity, n (%)
 Indigenous 4 0.2
 African-American 3 0.1
 Mestizo 2745 99.7

Education level, n (%)
 Elementary or none 787 28.6
 High school 1781 64.7
 University degree 284 6.7

CKD etiology, n (%)
 Hypertension 1660 60.3
 Diabetes 506 18.4
 Urinary tract obstruction 122 4.4
 Glomerulonephritis 84 3.1
 Polycystic kidney disease 34 1.2
 Other 222 8.1
 Unknown 124 4.5

History of cardiovascular disease, n (%) 122 4.4
Glomerular filtration rate ml/min/1.73 m2, mean (SD) 43.2 9.8
CKD stage G3, n (%) 2436 88.5
CKD stage G4, n (%) 316 11.5
Body mass index, mean (SD) kg/m2 26.8 4.3
Systolic blood pressure mmHg, mean (SD) 134.4 20.8
Diastolic blood pressure mmHg, mean (SD) 74.4 11.7
Serum albumin g/dL mean (SD) 4.2 0.3
Hemoglobin g/dL mean (SD) 14.3 1.9
Blood urea nitrogen mg/dL, median (IQR) 25 21, 33
Uric acid mg/dL mean (SD) 6.7 1.6
Glycosylated hemoglobin %, median (IQR)  7 6, 8
LDL cholesterol mg/dL, median (IQR) 114 91, 1
24-hours proteinuria, g/L, median (IQR) ∗∗ 0.1 0.1, 0.4
Use of ACEIs and ARBs, n (%) 450 16.4
Follow-up time, years, median (IQR) 5.2 3.1, 7.1

Data available only in diabetes patients.  ∗∗Data available in 1795 patients. CKD: chronic kidney disease; ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin ii receptor blockers; LDL: low-density lipoprotein.